The immune mechanisms that lead to specific autoimmune conditions are largely unknown. What we are missing most is a clear description of the steps involved. The anti-Sm response is closely associated with systemic lupus erythematosus (SLE) in man and both induced and genetic models in animals. We have """"""""identified PPPGMRPP as the first humeral epitope in Sm BIB"""""""" in patients that develop anti-Sm under observation (but who are already past clinical disease onset). We have also collected 633 sera from 130 individuals who up to nine years later developed SLE. These sera are not replaceable. In ordinary clinical practice no samples are available from before the onset of clinical disease. Indeed, to find such sera would require a project to prospectively collect sera from millions of normal individuals and then retrieve the sera from those who later developed lupus. Fortunately, exactly this has been done in the US military where the Army/Navy Serum Repository has collected over 20,000,000 samples. In the NIAID funded proposal R01 AI31584 to which this current R21 proposal is linked, we identified 130 Active Duty Military with SLE and have obtained their 633 samples and those of 520 matched controls. There are only small volumes of these sera available (about 0.5 ml) and the current technology cannot comprehensively address the question of the earliest structure identified by the immune system. To overcome this technological hurdle, we propose to adapt an optical fiber microsphere technology to determine rigorously whether PPPGMRPP is the first epitope or not. Under the proposed configuration the volume of serum required would be 1500-fold lower than required by our current technology, thereby permitting evaluation of all the overlapping octapeptides of Sm BIB', Sm D1, Sm D2, and Sm D3 with only 1 microliter of this irreplaceable resource and leaving over 99 percent of the resource for other experiments. Theoretically, the first autoimmune epitope has the potential to be critically important. This is the structure against which B cell tolerance (or ignorance) mechanisms are broken and this is the recognition event that all subsequent epitopes are likely to be dependent. In addition, the immune history leading to recognition of this epitope has the potential to reveal the etiology of lupus. These sera present our best opportunity to understand humeral autoimmunity in SLE before diagnosis. Moreover, once the microsphere technology is adapted to this important question, it will be amenable to addressing many other research and marketplace applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI053747-02
Application #
6787249
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Johnson, David R
Project Start
2003-08-05
Project End
2007-07-31
Budget Start
2004-08-01
Budget End
2007-07-31
Support Year
2
Fiscal Year
2004
Total Cost
$231,750
Indirect Cost
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Morris, D L; Fernando, M M A; Taylor, K E et al. (2014) MHC associations with clinical and autoantibody manifestations in European SLE. Genes Immun 15:210-7
Ko, Kichul; Franek, Beverly S; Marion, Miranda et al. (2012) Genetic ancestry, serum interferon-? activity, and autoantibodies in systemic lupus erythematosus. J Rheumatol 39:1238-40
Weckerle, Corinna E; Mangale, Dorothy; Franek, Beverly S et al. (2012) Large-scale analysis of tumor necrosis factor ? levels in systemic lupus erythematosus. Arthritis Rheum 64:2947-52
James, Judith A; Robertson, Julie M (2012) Lupus and Epstein-Barr. Curr Opin Rheumatol 24:383-8
Niewold, Timothy B; Kelly, Jennifer A; Kariuki, Silvia N et al. (2012) IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 71:463-8
Weckerle, Corinna E; Franek, Beverly S; Kelly, Jennifer A et al. (2011) Network analysis of associations between serum interferon-? activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 63:1044-53
Harley, Isaac T W; Niewold, Timothy B; Stormont, Rebecca M et al. (2010) The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol 2010:
Barcellos, Lisa F; May, Suzanne L; Ramsay, Patricia P et al. (2009) High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 5:e1000696
Niewold, Timothy B; Kelly, Jennifer A; Flesch, Marie H et al. (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58:2481-7
Han, Shizhong; Guthridge, Joel M; Harley, Isaac T W et al. (2008) Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. PLoS One 3:e0001757

Showing the most recent 10 out of 31 publications